Summary:
- This article discusses the results of a clinical trial that evaluated the use of the drug tucatinib in combination with trastuzumab and capecitabine for the treatment of advanced HER2-positive breast cancer.
- The study found that this combination therapy significantly extended the median progression-free survival (PFS) to over 2 years, compared to the control group.
- These findings suggest that the addition of tucatinib to the standard trastuzumab and capecitabine regimen can improve outcomes for patients with advanced HER2-positive breast cancer, a particularly aggressive form of the disease.